Emerine salicylate oral liquid and its prepn
The present invention discloses one kind of emerine salicylate oral liquid prepared with emerine salicylate, sodium pyrosulfite, citric acid, ethyl hydroxyl benzoate, disodium edentate, etc. Of the emerine salicylate oral liquid, emerine salicylate is atropine antagonist to inhibit central AChE acti...
Saved in:
Main Author | |
---|---|
Format | Patent |
Language | English |
Published |
22.08.2007
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention discloses one kind of emerine salicylate oral liquid prepared with emerine salicylate, sodium pyrosulfite, citric acid, ethyl hydroxyl benzoate, disodium edentate, etc. Of the emerine salicylate oral liquid, emerine salicylate is atropine antagonist to inhibit central AChE activity and maintain relevant skeletal muscle contractility, citric acid is used to regulate pH to 4.8-5.6, and sodium pyrosulfite and disodium edentate are added to avoid the oxidation and hydrolysis of emerine salicylate. Compared with similar medicine, the emerine salicylate oral liquid of the present invention has the advantages of determined curative effect, less side effect and low cost, and is used in treating bulbar patalysis, cerebrellar ataxia, etc. |
---|---|
Bibliography: | Application Number: CN20071200308 |